MUC16 and mesenchymal chondrosarcoma: Although there are only two cases, considering the rarity of mesenchymal chondrosarcoma, the identification of the MUC16 mutation indicates the potential opportunity of mesenchymal chondrosarcoma patients to benefit from immunotherapy.